FDA
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $40 at Guggenheim
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); LuxUrban Hotels Inc. (OTC: LUXH); and Unicycive Therapeutics, Inc. (NA
-
-
-
-
-
-
-
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
-
322,086 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

